The Top 5 Biosimilar Articles for the Week of November 13

Hi, I’m Skylar Jeremias for The Center for Biosimilars^®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of November 13, 2023.

Number 5: In part 1 of a 3-part series for Global Biosimilars Week, The Center for Biosimilars looks at a retrospective study comparing the clinical benefits, price changes, and uptake associated with oncology biosimilars in China.

Number 4: At the recent Academy of Managed Care Pharmacy Nexus meeting, panelists discussed the impact of introducing biosimilars in new medical fields, emphasizing the need for more education and collaboration to ensure their smooth integration into health care systems.

Number 3: A real-world analysis from Japan confirmed that CT-P13, an intravenous infliximab biosimilar, had comparable safety and efficacy to the reference product (Remicade; infliximab) in patients with immune-mediated inflammatory diseases.

Number 2: The use of biosimilars of tumor necrosis factor (TNF) inhibitors within Poland’s public payer saved over €243 million from 2013 to 2021, with about 68% of that coming from the rheumatic musculoskeletal diseases alone.

Number 1: Samsung Bioepis releases data for its denosumab biosimilar candidate; the Community Oncology Alliance (COA) forms the Drug Policy and Regulation Committee; the International Generic and Biosimilar Association (IGBA) and the World Health Organization (WHO) collaborate on a new initiative.

To read all of these articles and more, visit centerforbiosimilars.com.